<DOC>
	<DOCNO>NCT00225017</DOCNO>
	<brief_summary>The purpose study evaluate change brachial artery reactivity HIV-infected subject elevate lipid level switch atazanavir contain antiretroviral regimen</brief_summary>
	<brief_title>Switch Atazanavir Brachial Artery Reactivity ( SABAR ) Study</brief_title>
	<detailed_description>HIV-infected subject stable protease inhibitor ( PI ) contain antiretroviral regimen plasma HIV RNA &lt; 500 copies/mL , LDL cholesterol level &gt; 130 mg/dL fast triglyceride level &gt; 200 mg/dL , randomize ( 1:1 ) continue current antiretroviral regimen switch PI atazanavir ( ATV ) . Brachial artery reactivity measure ( entry ) 12 24 week subject randomize . ARM A : Switch current PI atazanavir 400 mg daily plus current &gt; 2 nucleoside/nucleotide reverse transcriptase inhibitor ( NRTIs ) 24 week . Subjects currently ritonavir ( RTV ) ( 400 mg BID great ) RTV-boosted PI ( &lt; 400 mg/day ) , tenofovir ( TDF ) backbone NRTI therapy , switch ATV 300 mg boost RTV 100mg daily . ARM B : Continue current antiretroviral regimen ( single RTV-boosted PI plus &gt; 2 NRTIs ) 24 week Brachial artery reactivity response two vasoactive stimulus ( increase forearm blood flow nitroglycerin ) assess measure brachial artery diameter .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>HIV infection HIV1 RNA &lt; 500 copies/ml Fasting LDL cholesterol &gt; 130 mg/dl OR fast triglyceride &gt; 200 mg/dl CD4 count &gt; 100 cells/mm Stable antiretroviral regimen least 12 week prior study entry include protease inhibitor ( PI ) without ritonavir boost History heart disease , uncontrolled hypertension , peripheral vascular disease Current nonnucleoside reverse transcriptase inhibitor ( NNRTI ) PIcontaining regimen within 4 week Prior current use atazanavir Initiation treatment lipidlowering drug within 4 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Atazanavir</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>